EMA Withdrawn: Telzir (fosamprenavir calcium) — ViiV Healthcare BV

View source ↗

Summary

The European Medicines Agency has withdrawn the marketing authorization for Telzir (fosamprenavir calcium) for HIV infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Telzir (fosamprenavir calcium)

Snippet

Status: Withdrawn. Therapeutic area: HIV Infections. MAH: ViiV Healthcare BV. Decision date: 19/08/2022